Key result
Rofecoxib significantly increased the risk of thrombotic cardiovascular adverse events compared to naproxen (RR 2.36; 95% CI 1.38-4.02; P=0.002).
Why the study?
Do selective COX-2 inhibitors increase cardiovascular risk compared to non-selective NSAIDs?
Do selective COX-2 inhibitors increase cardiovascular risk compared to non-selective NSAIDs?
Relative Risk: 2.36 (95% CI 1.38–4.02)
p-value: p=0.002
No takes yet. Share an insight, caveat, or question.
Large trial data indicate that COX-2 inhibitors do not offer a safety advantage over non-selective NSAIDs and may increase thrombotic cardiovascular events.
Stephan Schwarz (2003) conducted a letter in Postoperative pain (n=16,135). COX-2 inhibitors (celecoxib, rofecoxib) vs. Non-selective NSAIDs (naproxen) was evaluated on Thrombotic cardiovascular adverse events (RR 2.36, 95% CI 1.38-4.02, p=0.002). Rofecoxib significantly increased the risk of thrombotic cardiovascular adverse events compared to naproxen (RR 2.36; 95% CI 1.38-4.02; P=0.002).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: